Jae  Jung,  PhD

Jae Jung, PhD

Department Chair

Betsy B. deWindt Endowed Chair in Cancer Biology

Lerner Research Institute, 9500 Euclid Avenue, Cleveland, Ohio 44195
Phone: (216) 445-3377

 

Dr. Jung’s cancer research focuses on virus-induced cancers, including Kaposi’s sarcoma, the most common tumor in patients with AIDS. For his work in this disease area, the National Cancer Institute awarded him the prestigious Outstanding Investigator Award in 2016.

Dr. Jung leads the Department of Cancer Biology and the newly-established Global Center for Pathogen Research & Human Health, which is focused on broadening understanding of emerging pathogens.

Dr. Jung has several research projects related to coronaviruses, including vaccine and drug development, and has developed one of the first preclinical models to study SARS-CoV-2 infection and transmission to lead to the development of a COVID-19 vaccine. His vaccine work utilizes nanoparticles that compel the coronavirus to use its own surface protein to produce antibodies that block viral infection. The hope is that this approach will have fewer side effects than other vaccines, especially among the older population that is particularly susceptible to COVID-19.

Dr. Jung and a multi-disciplinary team of scientists and clinicians in Ohio and Florida are collaborating to uncover the mechanisms of infectious agents and virus-induced cancers. He leads virology, immunology and oncology researchers working to make laboratory discoveries about how pathogens spread and cause disease and will collaborate with Cleveland Clinic’s Center for Therapeutics Discovery. He recently received a $2.8 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine for a newly emerging tick-borne disease.


Selected peer-reviewed publications:

View complete PubMed search for Jae U. Jung.

  1. Kim et al. Infection and Rapid Transmission of the 2019 Novel Coronavirus in Ferrets. 2020 Cell Host & Microbe In Press.
  2. Chang et al. Critical role of OASL in DAI/RIPK3/MLKL axis-driven necroptosis against viral infection. 2020 Cell Host & Microbe in review.
  3. Park et al. Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functional MYC super-enhancers and enhancer RNAs. Proc Natl Acad Sci U S A. 2020 In Press
  4. Choi et al. Oncogenic human herpesvirus hijacks proline metabolism for tumorigenesis. Proc Natl Acad Sci U S A. 2020 In Press.
  5. Chen W et al. Zika virus NS3 protease induces fetal brain calcification. 2020 Nature Microbiology revision.
  6. Kwak et al. Development of a DNA vaccine for SFTSV that confers complete protection against lethal infection in ferrets. 2019 Nature Comm 10:3836.
  7. Chen ST et al. NLRP12 regulates anti-viral RIG-I activation via interaction with TRIM25. 2019 Cell Host & Microbe 25:602-616.
  8. Choi YJ et al. SerpinB1-mediated checkpoint of inflammatory caspase activation. 2019 Nature Immunology. 20(3):276-287.
  9. Srikanth S. et al. STIM1 regulates type I interferon response by retaining STING at the endoplasmic reticulum. 2019 Nature Immunology. 20(2):152-162.
  10. Choi YH et al. Severe fever with thrombocytopenia syndrome phlebovirus nonstructural protein activates TPL2 signalling pathway for viral immunopathogenesis. 2019 Nature Microbiology. 4(3):429-437.
  11. Park SJ et al.  Ferret model of severe fever with thrombocytopenia syndrome virus infection that recapitulates human clinical manifestations. 2019 Nature Microbiology. 4(3):438-446.
  12. Eoh H, Jung JU. Bacterial protein reshapes host defense toward antiviral responses. 2018. Mol Cell. 71:483.
  13. Choi YJ et al. A Talented Duo: IFIT1 and IFIT3 Patrol Viral RNA Caps. 2018 Immunity. 48:474.
  14. Seo et al. TRIM56-mediated monoubiquitination of cGAS for cytosolic DNA sensing. 2018 Nature Comm. 9:613.
  15. Choi et al. Double-edged sword of autophagy for viral replication and pathogenesis. 2018 Nature Rev Microbiol.
  16. Foo et al. Differential immunomodulatory responses of CD14+blood monocytes upon infection with different lineages of Zika virus. 2017 Nature Microbiology. 2:1558-1570.
  17. Chen W, Choi YJ, Jung JU. Unexpected alliance of WHIP-TRIM14-PPP6C to Combat Viruses. 2017 Mol Cell. 19: 259-261.
  18. Choi et al. Double the trouble When two herpesviruses join hands. 2017 Cell Host & Microbe. 22:5-6.
  19. Kwak et al. Identification and structure of the substrate-recognition module in the Dot/Icm type IV coupling protein complex of L. pneumophila. 2017. Nature Microbiology. 2:1-13.
  20. Chen et al. Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. 2017 Nature Comm. 9:13882.
  21. Liang et al. Zika Virus NS4A-NS4B inhibition of Akt-mTOR pathway contributes to neurogenesis defect and autophagy induction of human fetal neural stem cells. 2016 Cell Stem Cell. 19:663.
  22. Lee et al. Transformation of glutamyl-prolyl tRNA synthetase into an antiviral molecule via infection-specific modification. 2016 Nature Immunology. 7:1252.
  23. Lee et al. TPL2 Is an oncogenic driver in keratocanthoma and squamous cell carcinoma. 2016 Cancer Res. In press.
  24. Toth et al. LANA-mediated recruitment of host Polycomb Repressive Complexes onto the KSHV genome during de novo infection. 2016 PLoS Pathogen. 12(9):e1005878.
  25. Seo et al. No Trifling matter on STING. 2016 Cell Host & Microbe. 20(3):277-8
  26. Zhu et al. An oncogenic virus promotes cell survival and cellular transformation by suppressing glycolysis. 2016 PLoS Pathogens. 12(5):e1005648.
  27. Choi et al. HDAC6 regulates the cellular viral RNA sensing by deacetylation of RIG-I. EMBO J. 2016 Feb 15;35(4):429-42.
  28. Seo et al. AKT-mediated checkpoint of cGAS DNA sensing pathway. 2015 Cell Report. 13(2):440-9.
  29. Yoo et al. The mitochondrial E3 ubiquitin ligase MARCH5 negatively regulates the MAVS-mediated innate immune response. 2015 Nature Communication. 6:7910.
  30. Zhang Jet al. Herpesviral G protein-coupled receptors activate NFAT to induce tumor formation via inhibiting the SERCA calcium ATPase. 2015 PLoS Pathogen. 11(3):e1004768.
  31. Chen et al. Harnessing negative B cell selection to overcome drug-resistance in Ph+ acute lymphoblastic leukemia. 2015 Nature. 521:357-361
  32. He et al. Herpesviral Pseudo-enzymes Induce RIG-I Deamination and Ligand-independent Activation. 2015 Mol Cell. 58:134-146.
  33. Liang et al. Novel functions of viral anti-apoptotic factors. 2015 Nat Rev Microbiol. 13:7-12.
    Lee et al. Exploitation of Complement System by Oncogenic Kaposi’s Sarcoma-Associated Herpesvirus for Cell Survival and Persistent Infection. 2014 PLoS Pathogens. 10:e1004412
  34. Shi et al. Negative regulation of NF-B activity by brain-specific TRIpartite Motif protein 9. 2014 Nature Communication. 5:4820./
  35. Fan et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase. 2014 Journal of Experimental Medicine. 211:313-28.
  36. Rodgers et al. Ubiquitination-mediated activation of NLRP3-inflammasome activity. 2014 Journal of Experimental Medicine. 211:1333-47.
  37. Full et al. Kaposi’s sarcoma associated herpesvirus tegument protein ORF75 is essential for viral lytic replication and plays a critical role in the antagonization of ND10-instituted intrinsic immunity. 2014 PLoS Pathogen. 10:e1003863.
  38. Liang Q et al. cGAS and Beclin-1 interaction shapes innate immune responses by regulating cGAMP production and autophagy pathway. 2014 Cell Host & Microbe. 15: 228-238.
    Toth Z et al. Biphasic euchromatin-to-heterochromatin transition on the KSHV genome following de novo infection. 2013 PLoS Pathogen. 9(12):e1003813.
  39. Amini-Bavil-Olyaee S, et al. A novel mechanism of IFITM-mediated anti-viral activity. 2013 Cell Host Microbe. 13:452-464.
  40. Yang CS et al. Rubicon autophagic protein is a feedback inhibitor of CARD9-mediated host innate immunity. 2012 Cell Host & Microbe. 11:277-289.
  41. Yang CS et al. Rubicon autophagic protein is a positive regulator of the reactive oxygen species generating NADPH oxidase complex. 2012 Cell Host & Microbe. 11:262-276.
  42. Lee HR et al. Viral peptide inhibitors of HAUSP to induce apoptosis. 2011 Nature Structural & Molecular Biology. 18:1336-1344.
  43. Inn KS et al. Linear Ubiquitin Assembly Complex Negatively Regulates RIG-I- and TRIM25-Mediated Type I Interferon Induction. 2011 Mol Cell. 41:354-65.
  44. Toth et al. Epigenetic regulation of latency and reactivation of Kaposi’s sarcoma-associated herpesvirus. 2010 PLoS Pathogen. 6(7):e10013
  45. Chang et al. Nonhuman primate model for KSHV persistent infection. 2009 PLoS Pathogen. 5(10):e1000606.
  46. E X et al. Viral Bcl-2- mediated evasion of autophagy aids chronic infection of gherpesvirus 68. 2009 PLoS Pathogen. 5(10):e1000609.
  47. Gack et al. Inhibition of TRIM25-mediated RIG-I anti-viral activity by Influenza A virus. 2009 Cell Host & Microbes. 5(5):439-49.
  48. Myong et al. Cytosolic viral sensor RIG-I is a 5’-triphosphate dependent translocase on double stranded RNA. 2009 Science. 323:1070-1074.
  49. Lee et al. FLIP-mediated cell death control. 2009 Nature Cell Biology. 11:1355-62
  50. Min CK et al. The role of membrane-proximal amphipathic helix of Tip in membrane deformation and TCR downregulation. 2008 PLoS Pathogen. 4(11):e1000209.
  51. Ku et al. Structural and biochemical bases for the inhibition of autophagy and apoptosis by viral BCL-2 of murine gamma-herpesvirus 68. PLOS Pathogen. 2008 4(2):e25
  52. Gack et al. Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction Proc Natl Acad Sci U S A. 2008 105(43): 16743-16748.
  53. Liang et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nature Cell Biology. 2008 Jul;10(7):776-87
  54. Feng et al. A novel inhibitory mechanism of mitochondrion-dependent apoptosis by a herpesviral protein. PLoS Pathog. 2007 Dec;3(12):e174.
  55. Takahashi et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol. 2007 Oct;9(10):1142-51.
  56. Gack et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007 Apr 19;446(7138):916-920.
  57. Liang et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nat Cell Biol. 2006 Jul;8(7):688-99.
  58. Cho et al. Inhibition of T cell receptor signal transduction by tyrosine kinase-interacting protein of Herpesvirus saimiri. J Exp Med. 2004 Sep 6;200(5):681-7.
  59. Park et al. Herpesviral protein targets a cellular WD repeat endosomal protein to downregulate T lymphocyte receptor expression. Immunity. 2002 Aug;17(2):221-33.
  60. Means et al. Multiple endocytic trafficking pathways of MHC class I molecules induced by a Herpesvirus protein. EMBO J. 2002 Apr 2;21(7):1638-49.
  61. Ishido et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi’s sarcoma-associated herpesvirus K5 protein. Immunity. 2000 Sep;13(3):365-74.
  62. Lee et al. Inhibition of intracellular transport of B cell antigen receptor complexes by Kaposi’s sarcoma-associated herpesvirus K1. J Exp Med. 2000 Jul 3;192(1):11-21.
  63. Lee et al. Deregulation of cell growth by the K1 gene of KSHV. 1998. Nature Medicine. 4:435-440.
  64. Yoon et al. Tap; a novel cellular protein that interacts with tip of herpesvirus saimiri and induces lymphocyte aggregation. Immunity. 1997; 6:571-582.
  65. Duboise et al. Use of virion DNA as a cloning vector for the construction of mutant and recombinant herpesviruses. Proc. Natl. Acad. Sci.. 1996; 93:11389-11394.
  66. Du et al. Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys. Cell. 1995; 82:665-674
  67. Jung et al. Identification of transforming genes of subgroup A and C strains of Herpesvirus saimiri. Proc. Natl. Acad. Sci. USA. 1991; 88:7051-7055


06/30/2021 |  

Dr. Jung Appointed to Betsy B. deWindt Endowed Chair in Cancer Biology

Jae Jung, PhD, chair of the Department of Cancer Biology and director of the Global Center for Pathogen Research & Human Health, has been named the Betsy B. deWindt Endowed Chair in Cancer Biology.  




03/02/2021 |  

Nanoparticle-delivered COVID-19 Vaccine Candidate Shows Promise in Preclinical Studies

Researchers from Cleveland Clinic’s Global Center for Human Health & Pathogen Research have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models.




03/02/2021 |  

Characterizing Patient Immune Responses to Emerging Tick-borne Virus

Researchers led by Jae Jung, PhD, director of Cleveland Clinic’s Global Center for Pathogen Research & Human Health, have performed the first comprehensive immunoprofiling study of patients with severe fever with thrombocytopenia syndrome (SFTS), an emerging tick-borne disease.




01/28/2021 |  

Study Reveals Cause of Common Zika Virus Birth Defect

Researchers have described for the first time how Zika virus (ZIKV) causes one of the most common birth defects associated with prenatal infection, called brain calcification, according to new study findings published in Nature Microbiology.




01/25/2021 |  

Cleveland Clinic Announces New Global Center for Pathogen Research & Human Health

Cleveland Clinic will significantly expand its global commitment to infectious disease research and translational programs to form the Global Center for Pathogen Research & Human Health, made possible as part of the new Cleveland Innovation District announced today.




08/10/2020 |  

Cleveland Clinic Names Chair of Department of Cancer Biology

Cleveland Clinic has appointed Jae Jung, PhD, as chair of Lerner Research Institute’s Department of Cancer Biology. Dr. Jung will also serve as director of the new Center for Global and Emerging Pathogens Research, which will focus on public health threats ranging from Zika virus to SARS-CoV-2, which causes COVID-19.




08/10/2020 |  

$2.8M Grant Awarded to Develop Vaccine to Counter Emerging Tick-Borne Virus

Jae Jung, PhD, has received a five-year, $2.8 million award from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a vaccine to treat an emerging tick-borne infectious disease called severe fever with thrombocytopenia syndrome (SFTS). Importantly, this is the inaugural grant awarded to researchers in Cleveland Clinic’s newly created Center for Global and Emerging Pathogens, for which Dr. Jung serves as center director.